The incidence of ILD following anti-TNF-α use in RA patients was assessed by Curtis and colleagues.8 When the sensitive definition of ILD was used, unadjusted incidence rates (95% confidence interval, or CI) reached 12.2 (5.6–23.2) per 1000 person-years in the infliximab group. Here, TNF is linked to interstitial lung disease.